Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Casimersen (Primary) ; Golodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Sponsors Sarepta Therapeutics
- 16 Nov 2018 Planned number of patients changed from 150 to 260.
- 16 Nov 2018 Planned End Date changed from 30 Jun 2024 to 30 Jun 2026.
- 16 Nov 2018 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2026.